Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 4, 2012, Pages 391-399.e1

  Hyams, Jeffrey ^a   Damaraju, Lakshmi ^b   Blank, Marion ^b   Johanns, Jewel ^b   Guzzo, Cynthia ^b   Winter, Harland S ^c   Kugathasan, Subra ^d   Cohen, Stanley ^e   Markowitz, James ^f   Escher, Johanna C ^g   Veereman Wauters, Gigi ^h   Crandall, Wallace ⁱ   Baldassano, Robert ^j   Griffiths, Anne ^k  

^a Farmington   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Children's Center for Digestive Health Care   (United States)

^f Northwell Health   (United States)

^g SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^h Queen Paola Children's Hospital   (Belgium)

ⁱ NATIONWIDE CHILDREN S HOSPITAL   (United States)

^j CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^k HOSPITAL FOR SICK CHILDREN   (Canada)

more..

Author keywords

Clinical trial; Inflammatory bowel disease (IBD); Mucosal healing; Pediatric ulcerative colitis activity index (PUCAI)

Indexed keywords

INFLIXIMAB;

ADOLESCENT; ARTICLE; CHILD; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRESCHOOL CHILD; RECTUM HEMORRHAGE; SCHOOL CHILD; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 84858700602     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.11.026     Document Type: Article

References (20)

1. Baldassano R.N., Piccoli D.A. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am 1999, 28:445-458.
2. Kelsen J., Baldassano R.N. Inflammatory bowel disease: the difference between children and adults. Inflamm Bowel Dis 2008, 14(Suppl 2):S9-S11.
3. Sauer C.G., Kugathasan S. Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Gastroenterol Clin North Am 2009, 38:611-628.
4. Turner D., Griffiths A.M. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 2011, 17:440-449.
5. Hyams J., Markowitz J., Lerer T., et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006, 4:1118-1123.
6. Ringheanu M., Markowitz J. Inflammatory bowel disease in children. Curr Treat Options Gastroenterol 2002, 5:181-196.
7. Hyams J., Lerer T., Mack D., et al. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol 2011, 106:981-987.
8. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
9. Hyams J., Crandall W., Kugathasan S., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007, 132:863-873.
10. Eidelwein A.P., Cuffari C., Abadom V., et al. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005, 11:213-218.
11. Mamula P., Markowitz J.E., Brown K.A., et al. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2002, 34:307-311.
12. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987, 317:1625-1629.
13. Turner D., Otley A.R., Mack D., et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterolology 2007, 133:423-432.
14. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
15. Data on file, Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, 2010.
16. Turner D., Mack D., Leleiko N., et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010, 138:2282-2291.
17. Hyams J.S., Lerer T., Griffiths A., et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 2010, 105:1430-1436.
18. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121-1125.
19. Mackey A.C., Green L., Liang L.C., et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:265-267.
20. Mackey A.C., Green L., Leptak C., et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009, 48:386-388.